Mottiwala Aziz
SEC insider (Form 3/4/5 filer). CIK 0001788542. President and CEO at RxSight, Inc. (RXST) and 1 other issuer. 15 reported Form 4/5 transactions since Sep 2024; latest on Jul 24, 2026. Located in ALISO VIEJO, CA.
Companies Mottiwala Aziz has filed insider reports for
- RxSight, Inc. (RXST): Director, Officer, President and CEO
- Tarsus Pharmaceuticals, Inc. (TARS): Officer, Chief Commercial Officer
Mottiwala Aziz
CIK: 0001788542
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jul 24, 2026RXST
RxSight, Inc.
AwardDirectRestricted Stock Unit
2.3M shares- - Jul 24, 2026RXST
RxSight, Inc.
AwardDirectStock Option (right to buy)
571.3K shares- - Mar 19, 2026TARS
Tarsus Pharmaceuticals, Inc.
SaleDirect4.4K shares at avg. $67.00$297K - Mar 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
SaleDirect4.3K shares at avg. $68.71$298K - Mar 17, 2026TARS
Tarsus Pharmaceuticals, Inc.
SaleDirect4.3K shares at avg. $69.42$298K - Mar 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
ExerciseDirect26.5K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
AwardDirectStock Option (right to buy)
30.7K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
AwardDirectRestricted Stock Units
19.3K shares- - Jun 9, 2025TARS
Tarsus Pharmaceuticals, Inc.
SaleDirect17.5K shares at avg. $43.76$766K - Mar 20, 2025TARS
Tarsus Pharmaceuticals, Inc.
SaleDirect3.4K shares at avg. $50.11$169K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 24, 2026 |  RXST RxSight, Inc. | Award Restricted Stock Unit | 2,312,138 | - | - | Direct |
| Jul 24, 2026 | RXST RxSight, Inc. | Award Stock Option (right to buy) | 571,286 | - | - | Direct |
| Mar 19, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Sale | 4,440 | $67.00 | $297,480 | Direct |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale | 4,330 | $68.71 | $297,514 | Direct |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale | 4,286 | $69.42 | $297,534 | Direct |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise | 26,482 | - | $0 | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award Stock Option (right to buy) | 30,724 | - | - | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award Restricted Stock Units | 19,306 | - | - | Direct |
| Jun 9, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale | 17,500 | $43.76 | $765,800 | Direct |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale | 3,365 | $50.11 | $168,620 | Direct |
1-10 of 15 transactions